Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€53.13

€53.13

-1.230%
-0.66
-1.230%
€62.00

€62.00

 
10:12 / Tradegate WKN: 850501 / Symbol: BMY / Name: Bristol-Myers / Stock / Pharmaceuticals / Large Cap /
Latest predictions
-
11.01.21
buy
€56.00
05.01.21
buy
-
03.01.21
buy
-
13.10.20
buy
€55.00
11.03.20
buy
€66.00
05.01.20
buy
Your prediction

Bristol-Myers Squibb Stock

We can see a decrease in the price for Bristol-Myers Squibb. Compared to yesterday it has lost -€0.660 (-1.230%).
With 12 Buy predictions and not the single Sell prediction the community is currently very high on Bristol-Myers Squibb.
As a result the target price of €62.00 shows a slightly positive potential of 16.695% compared to the current price of €53.13 for Bristol-Myers Squibb.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Bristol-Myers Squibb stock. Negative votes have not been in the majority for any criteria for this stock

Pros and Cons of Bristol-Myers Squibb in the next few years

Pros
1
Could be very worthwhile Investment >20% year
1
Revenue growth >5% per year expected
1
High dividend yield expected
Cons
0
-

Performance of Bristol-Myers Squibb vs. its peers

Security Change (%) 1w 1m 1y YTD 3y 5y
Bristol-Myers Squibb -1.230% 0.693% 1.147% -8.051% 6.938% 24.284% -14.991%
Elanco Animal Health Inc. 5.720% 8.430% 13.501% 55.922% 11.306% - -
Merck & Co. Inc. -0.510% 1.008% 1.909% -9.528% -1.898% 30.254% 36.734%
BioMarin Pharmaceutical Inc. -0.030% -4.943% -4.856% -29.291% -11.669% -16.875% -13.856%

Comments

Buy Bristol-Myers Squibb
Show more

Buy Bristol-Myers Squibb
Show more

Buy Bristol-Myers Squibb
Show more

Other discussions about Bristol-Myers Squibb Stock

Trading Bristol-Myers Squibb

Trading Bristol-Myers Squibb

New thread Forum

News

Bristol Myers Squibb Completes Acquisition of MyoKardia, Strengthening Company’s Leading Cardiovascular Franchise : http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23877/Bristol-Myers_Squibb_Logo.svg.png
Bristol Myers Squibb Completes Acquisition of MyoKardia, Strengthening Company’s Leading Cardiovascular Franchise


Bristol Myers Squibb (NYSE:BMY) announced today that it has successfully completed its acquisition of MyoKardia, Inc. in an all cash transaction for approximately $13.1 billion. With the completion